Research programme: intranasal therapeutic agents - Cognition Life Science

Drug Profile

Research programme: intranasal therapeutic agents - Cognition Life Science

Latest Information Update: 18 Jan 2016

Price : $50

At a glance

  • Originator University of South Florida
  • Developer Cognition Life Science; University of South Florida
  • Class Antidementias; Antiparkinsonians; Cannabinoids; Non-opioid analgesics
  • Mechanism of Action Cannabinoid receptor agonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Alzheimer's disease; Pain; Parkinson's disease; Sleep disorders

Most Recent Events

  • 13 Jan 2016 Early research in Alzheimer's disease, Parkinson's disease, Sleep disorders and Pain in USA (Intranasal) before January 2016
  • 13 Jan 2016 Cognition Life Science acquires proprietary formulations for the treatment of Neurodegenerative disorders, Sleep disorders, mental acuity and pain management from University of South Florida
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top